Kallenberg Judith, Mok Wilson, Newman Robert, Nguyen Aurélia, Ryckman Theresa, Saxenian Helen, Wilson Paul
Judith Kallenberg (
Wilson Mok is senior manager of price forecasting at Gavi.
Health Aff (Millwood). 2016 Feb;35(2):250-8. doi: 10.1377/hlthaff.2015.1079.
Gavi, the Vaccine Alliance, was created in 2000 to accelerate the introduction of new and underused vaccines in lower-income countries. The period 2000-15 was marked by the rapid uptake of new vaccines in more than seventy countries eligible for Gavi support. To stay focused on the poorest countries, Gavi's support phases out after countries' gross national income per capita surpasses a set threshold, which requires governments to assume responsibility for the continued financing of vaccines introduced with Gavi support. Gavi's funding will end in the period 2016-20 for nineteen countries that have exceeded the eligibility threshold. To avoid disrupting lifesaving immunization programs and to ensure the long-term sustainable impact of Gavi's investments, it is vital that governments succeed in transitioning from development assistance to domestic financing of immunization programs. This article discusses some of the challenges facing countries currently transitioning out of Gavi support, how Gavi's policies have evolved to help manage the risks involved in this process, and the lessons learned from this experience.
全球疫苗免疫联盟(Gavi)成立于2000年,旨在加速低收入国家引入新的和未充分使用的疫苗。2000年至2015年期间,70多个有资格获得Gavi支持的国家迅速采用了新疫苗。为了专注于最贫穷国家,当国家人均国民总收入超过设定门槛后,Gavi的支持将逐步退出,这要求各国政府承担起为在Gavi支持下引入的疫苗持续提供资金的责任。对于19个已超过资格门槛的国家,Gavi的资金将在2016年至2020年期间结束。为避免扰乱挽救生命的免疫计划,并确保Gavi投资产生长期可持续影响,各国政府成功地从发展援助过渡到国内为免疫计划提供资金至关重要。本文讨论了目前正从Gavi支持过渡的国家面临的一些挑战、Gavi的政策如何演变以帮助管理这一过程中涉及的风险,以及从这一经验中吸取的教训。